Personalized Psychiatry Market Report 2026

Personalized Psychiatry Market Overview

• Personalized Psychiatry market size has reached to $6.51 billion in 2025 • Expected to grow to $12.73 billion in 2030 at a compound annual growth rate (CAGR) of 14.3% • Growth Driver: Increasing Mental Health Issues Fueling The Growth Of The Market Due To Rising Stress And Lifestyle-Related Challenges • Market Trend: Telepsychiatry Advances Personalized Care With Genetics And Virtual Access • North America was the largest region in 2025.

What Is Covered Under Personalized Psychiatry Market?

Personalized psychiatry is a tailored approach to mental health care that integrates genetic, biological, environmental, and clinical data to customize diagnosis, treatment planning, and therapeutic interventions for individual patients, aiming to improve outcomes and reduce trial-and-error prescribing. It is used to enhance treatment efficacy, minimize adverse effects, and facilitate early intervention by aligning psychiatric care with an individual patient's unique biological and psychological profile. The main types of personalized psychiatry are products, services, and software. Personalized psychiatry products are tailored medical tools, diagnostics, or therapeutic solutions designed to support individualized mental health treatment based on a person's genetic, biological, and behavioral characteristics. The technologies in this are genetic testing, artificial intelligence, neurostimulation technology, and digital therapeutics used in applications such as depression, anxiety disorders, bipolar disorder, schizophrenia, and attention-deficit hyperactivity disorder (ADHD) in end-users such as clinics, hospitals, research institutes, and homecare settings.

What Is The Personalized Psychiatry Market Growth Forecast?

The personalized psychiatry market size is expected to see rapid growth in the next few years. It will grow to $12.73 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing demand for outcome-driven psychiatric treatments, rising integration of AI and genomics in mental healthcare, expansion of home-based and digital mental health solutions, growing emphasis on personalized drug efficacy, increasing investments in precision psychiatry platforms. Major trends in the forecast period include increasing adoption of pharmacogenomic-guided treatment planning, growing use of AI-driven clinical decision support tools, expansion of telepsychiatry-based personalized care models, rising integration of wearable and neuroimaging data, enhanced focus on early and accurate diagnosis.

Global Personalized Psychiatry Market Segmentation

1) By Type: Products, Services, Software 2) By Technology: Genetic Testing, Artificial Intelligence, Neurostimulation Technology, Digital Therapeutics 3) By Application: Depression, Anxiety Disorders, Bipolar Disorder, Schizophrenia, Attention-Deficit Hyperactivity Disorder (ADHD) 4) By End User: Clinics, Hospitals, Research Institutes, Homecare Settings Subsegments: 1) By Products: Pharmacogenomic Test Kits, Wearable Devices, Brain Imaging Devices 2) By Services: Telepsychiatry, Personalized Treatment Planning, Behavioral Assessment 3) By Software: Clinical Decision Support Tools, Mental Health Apps, Virtual Therapy Platforms

What Is The Driver Of The Personalized Psychiatry Market?

The increasing mental health issues are expected to propel the growth of the personalized psychiatry market going forward. Mental health issues refer to a wide range of conditions that affect a person's emotional, psychological, and social well-being. The increasing mental health issues are due to rising stress and lifestyle-related challenges, driven by fast-paced work environments, poor work-life balance, and limited coping mechanisms. Personalized psychiatry supports mental health issues by offering tailored treatment plans based on individual biological, psychological, and lifestyle factors. It enhances care effectiveness by reducing trial and error in treatment, leading to faster recovery and improved patient outcomes. For instance, in 2025, according to the National Alliance on Mental Illness and NextStep Solutions Behavioral Health, US-based health agencies reported that serious mental illness (SMI) prevalence was about 5.44% in 2023 of adults. Therefore, the increasing mental health issues are driving the growth of the personalized psychiatry industry.

Key Players In The Global Personalized Psychiatry Market

Major companies operating in the personalized psychiatry market are Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb, Takeda Pharmaceutical Company, Boehringer Ingelheim, Otsuka Pharmaceutical Co. Ltd., H. Lundbeck A/S, Neurocrine Biosciences, Spring Health, Neumora Therapeutics Inc., Atai Life Sciences, Valera Health, Compass Pathways, Genomind, Woebot Health, Meru Health, Alto Neuroscience, Arcara Personalized Psychiatry, Mind Sync Therapeutics, Starling Minds, HMNC Holding GmbH, Pear Therapeutics, Akili Interactive

Global Personalized Psychiatry Market Trends and Insights

Major companies operating in the personalized psychiatry market are focusing on developing technologically advanced services, such as personalized telepsychiatry services, to improve access to individualized mental health care through a flexible, patient-centered service model. Personalized telepsychiatry service is a remote mental healthcare approach that delivers tailored psychiatric evaluation and treatment based on an individual’s unique genetic, environmental, and lifestyle factors through digital communication platforms. For instance, in April 2025, Alice’s Psychiatry & Wellness, a US-based psychiatry and wellness service company, launched a clinic to provide compassionate, personalized psychiatric care to adults across multiple states through both in-person and telepsychiatry services. This clinic integrates pharmacogenetic testing to tailor psychiatric medications based on each patient’s genetic profile, enhancing treatment effectiveness and reducing adverse effects. The clinic leverages virtual platforms and continuous care from a dedicated provider to deliver accessible, consistent, and inclusive mental health support, fully aligned with the principles of personalized psychiatry.

What Are Latest Mergers And Acquisitions In The Personalized Psychiatry Market?

In March 2025, April Health Inc., a US-based behavioral health company, merged with Wysa Ltd. for an undisclosed amount. This merger aims to integrate Wysa's AI-driven mental health support with April Health's virtual behavioral health services, enhancing access to personalized behavioral healthcare through primary care providers. Wysa Ltd. is a US-based digital mental health company that uses artificial intelligence (AI) to provide personalized, evidence-based psychiatric support.

Regional Outlook

North America was the largest region in the personalized psychiatry market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Personalized Psychiatry Market?

The personalized psychiatry market consists of revenues earned by entities by providing services such as remote patient monitoring services for mental health, mental health coaching programs, medication management support, lifestyle and behavioral modification programs, cognitive assessment services, and in-home psychiatric care. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized psychiatry market also includes sales of biomarker-based diagnostic assays, neurofeedback equipment, point-of-care mental health diagnostic tools, personalized supplement formulations, and biosensor-integrated monitoring tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Personalized Psychiatry Market Report 2026?

The personalized psychiatry market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the personalized psychiatry industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.